8,8-diethyldihydroberberine | 71266-78-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 原小檗碱生物碱及其衍生物
• 英文名称: 8,8-diethyldihydroberberine
• 英文别名: 8,8-diethyl-9,10-dimethoxy-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline；8,8-diethyl-9,10-dimethoxy-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline；8,8-Diethyldihydroberberin；8,8-diethyl 9,10-dimethoxy-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline；14,14-diethyl-16,17-dimethoxy-5,7-dioxa-13-azapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(21),2,4(8),9,15(20),16,18-heptaene
• CAS: 71266-78-9
• 化学式: C₂₄H₂₇NO₄
• 分子量: 393.483
• InChiKey: SYFIMBLBFVCFAG-UHFFFAOYSA-N

物化性质

• 沸点：
  570.5±50.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  40.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8,8-diethyldihydroberberine 在 sodium tetrahydroborate 作用下， 生成 8,8-Diethylcanadin
  参考文献：
  名称：

  8-氯小ber碱的化学。

  摘要：

  通过用三氯氧磷处理氧小（碱（I）而获得的8-氯小ber碱（V）是反应性中间体。用氨，甲胺，正丙胺，苯胺和对甲苯胺处理提供了8-小ber碱亚烷基衍生物IV和VII-X。V与丙二腈，乙酰乙酸乙酯和丙二酸乙酯阴离子反应，得到8-小ber亚烷基衍生物XII-XIV。XIV的酸水解得到8-小ber碱乙酸（XV），其还原得到8-芥子酸（XVI）。格氏试剂容易与V.甲基碘化镁，乙基碘化镁和苄基碘化镁反应，分别生成8,8-二甲基二氢小ber碱（XVII），8,8-二乙基二氢小ber碱（XIX）和苄基衍生物XX。XX的硼氢化钠还原产生了8-苄基卡丹宁（XXI）。

  DOI：

  10.1002/jps.2600680613
• 作为产物：
  描述：

  小檗浸碱 在 三氯氧磷 作用下， 以 乙醚 为溶剂， 生成 8,8-diethyldihydroberberine
  参考文献：
  名称：

  8-氯小ber碱的化学。

  摘要：

  通过用三氯氧磷处理氧小（碱（I）而获得的8-氯小ber碱（V）是反应性中间体。用氨，甲胺，正丙胺，苯胺和对甲苯胺处理提供了8-小ber碱亚烷基衍生物IV和VII-X。V与丙二腈，乙酰乙酸乙酯和丙二酸乙酯阴离子反应，得到8-小ber亚烷基衍生物XII-XIV。XIV的酸水解得到8-小ber碱乙酸（XV），其还原得到8-芥子酸（XVI）。格氏试剂容易与V.甲基碘化镁，乙基碘化镁和苄基碘化镁反应，分别生成8,8-二甲基二氢小ber碱（XVII），8,8-二乙基二氢小ber碱（XIX）和苄基衍生物XX。XX的硼氢化钠还原产生了8-苄基卡丹宁（XXI）。

  DOI：

  10.1002/jps.2600680613

文献信息

• NOVEL ISOQUINOLINE DERIVATIVES
  申请人：Chen Li

  公开号：US20100286396A1

  公开（公告）日：2010-11-11

  The invention provides novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 to R 7 are as described herein, compositions including the compounds and methods of preparing and using the compounds.

  这项发明提供了式（I）的新化合物或其药用可接受盐，其中R1至R7如本文所述，包括这些化合物的组合物以及制备和使用这些化合物的方法。
• [EN] NOVEL ISOQUINOLINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'ISOQUINOLÉINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010128061A1

  公开（公告）日：2010-11-11

  A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R7 have the significance given in claim 1, can be used in the form of a pharmaceutical composition.

  化合物的结构式（I）或其药学上可接受的盐，其中R1至R7具有权利要求书中给定的含义，可用作药物组合物的形式。
• Isoquinoline derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US08258149B2

  公开（公告）日：2012-09-04

  The invention provides novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein, compositions including the compounds and methods of preparing and using the compounds.

  本发明提供了式(I)的新化合物或其药学上可接受的盐，其中R1至R7如本文所述，包括该化合物的组合物以及制备和使用该化合物的方法。
• 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models
  作者：Zhe Cheng、An-Feng Chen、Fang Wu、Li Sheng、Han-Kun Zhang、Min Gu、Yuan-Yuan Li、Li-Na Zhang、Li-Hong Hu、Jing-Ya Li、Jia Li

  DOI：10.1016/j.bmc.2010.06.085

  日期：2010.8

  The clinical use of the natural alkaloid berberine (BBR) as an antidiabetic reagent is limited by its poor bioavailability. Our previous work demonstrated that dihydroberberine (dhBBR) has enhanced bioavailability and in vivo efficacy compared with berberine. Here we synthesized the 8,8-dimethyldihydroberberine (Di-Me) with improved stability, and bioavailability over dhBBR. Similar to BBR and dhBBR, Di-Me inhibited mitochondria respiration, increased AMP:ATP ratio, activated AMPK and stimulated glucose uptake in L6 myotubes. In diet-induced obese (DIO) mice, Di-Me counteracted the increased adiposity, tissue triglyceride accumulation and insulin resistance, and improved glucose tolerance at a dosage of 15 mg/kg. Administered to db/db mice with a dosage of 50 mg/kg, Di-Me effectively reduced random fed and fasting blood glucose, improved glucose tolerance, alleviated insulin resistance and reduced plasma triglycerides, with better efficacy than dhBBR at the same dosage. Our work highlights the importance of dihydroberberine analogs as potential therapeutic reagents for type 2 diabetes treatment. (C) 2010 Elsevier Ltd. All rights reserved.
• 8,8-Dialkyldihydroberberines with Potent Antiprotozoal Activity
  作者：Molla Endeshaw、Xiaohua Zhu、Shanshan He、Trupti Pandharkar、Emily Cason、Kiran V. Mahasenan、Hitesh Agarwal、Chenglong Li、Manoj Munde、W. David Wilson、Mark Bahar、Raymond W. Doskotch、A. Douglas Kinghorn、Marcel Kaiser、Reto Brun、Mark E. Drew、Karl A. Werbovetz

  DOI：10.1021/np300638f

  日期：2013.3.22

  Semisynthetic 8,8-dialkyldihydroberberines (8,8-DDBs) were found to possess mid- to low-nanomolar potency against Plasmodium falciparum blood-stage parasites, Leishmania donovani intracellular amastigotes, and Trypanosoma brucei brucei bloodstream forms. For example, 8,8-diethyldihydroberberine chloride (5b) exhibited in vitro IC50 values of 77, 100, and 5.3 nM against these three parasites, respectively. In turn, two 8,8-dialkylcanadines, obtained by reduction of the corresponding 8,8-DDBs, were much less potent against these parasites in vitro. While the natural product berberine is a weak DNA binder, the 8,8-DDBs displayed no affinity for DNA, as assessed by changes in the melting temperature of poly(dA.dT) DNA. Selected 8,8-DDBs showed efficacy in mouse models of visceral leishmaniasis and African trypanosomiasis, with 8,8-dimethyldihydroberberine chloride (5a) reducing liver parasitemia by 46% in L. donovani-infected BALB/c mice when given at an intraperitoneal dose of 10 mg/kg/day for five days. The 8,8-DDBs may thus serve as leads for discovering new antimalarial, antileishmanial, and antitrypanosomal drug candidates.